219 related articles for article (PubMed ID: 26683805)
1. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
Cheah CY; Nastoupil LJ; McLaughlin P; Fanale MA; Neelapu SS; Fayad LE; Hagemeister FB; Fowler NH
Br J Haematol; 2016 Nov; 175(3):531-533. PubMed ID: 26683805
[No Abstract] [Full Text] [Related]
2. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
[TBL] [Abstract][Full Text] [Related]
3. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD;
Cancer Med; 2019 Nov; 8(16):6955-6966. PubMed ID: 31573746
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
D'Alò F; Malafronte R; Piludu F; Bellesi S; Cuccaro A; Maiolo E; Modoni A; Leccisotti L; Macis G; Mores N; De Stefano V; Hohaus S
Br J Haematol; 2020 May; 189(4):e140-e144. PubMed ID: 32150646
[No Abstract] [Full Text] [Related]
5. Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.
Yamasaki S; Matsushima T; Minami M; Kadowaki M; Takase K; Iwasaki H
Ann Hematol; 2022 Jan; 101(1):209-211. PubMed ID: 33392703
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
7. Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature.
Farris M; Hughes RT; Lamar Z; Soike MH; Menke JR; Ohgami RS; Winkfield K
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e1-e8. PubMed ID: 30396823
[TBL] [Abstract][Full Text] [Related]
8. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
[No Abstract] [Full Text] [Related]
10. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S
Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012
[No Abstract] [Full Text] [Related]
11. Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.
Masamoto Y; Shimura A; Honda A; Taoka K; Maki H; Kurokawa M
Ann Hematol; 2023 Jan; 102(1):243-244. PubMed ID: 36369496
[No Abstract] [Full Text] [Related]
12. Lichenoid drug eruption associated with Bendamustine.
Kusano Y; Terui Y; Yokoyama M; Hatake K
Blood Cancer J; 2016 Jun; 6(6):e438. PubMed ID: 27341077
[No Abstract] [Full Text] [Related]
13. Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study.
Saburi M; Okuhiro K; Yoshida N; Haruyama T; Moroga Y; Yanai Y; Itani K; Takano K; Honda S; Ono K; Iwanaga M; Sasaki H; Abe M; Kohno K; Nakayama T; Ohtsuka E; Ogata M
J Clin Exp Hematop; 2023 Sep; 63(3):197-200. PubMed ID: 37518273
[No Abstract] [Full Text] [Related]
14. Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.
Lucijanic M; Jaksic O
Ann Hematol; 2020 Sep; 99(9):2191-2192. PubMed ID: 32556456
[No Abstract] [Full Text] [Related]
15. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
16. Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
Takezaki T; Nakazaki K; Toyama K; Matsuda K; Kogure Y; Chiba A; Nakamura F; Honda A; Kurokawa M
Hematol Oncol; 2021 Oct; 39(4):465-472. PubMed ID: 33934368
[TBL] [Abstract][Full Text] [Related]
17. Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.
Cerchione C; Nappi D; Musuraca G; Lucchesi A; Cimmino I; Pane F; De Renzo A; Martinelli G
Medicine (Baltimore); 2020 Aug; 99(33):e21440. PubMed ID: 32871991
[TBL] [Abstract][Full Text] [Related]
18. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
20. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
Olszewski AJ; Reagan JL; Castillo JJ
Am J Hematol; 2018 Jan; 93(1):E1-E3. PubMed ID: 28960532
[No Abstract] [Full Text] [Related]
[Next] [New Search]